Abstract Substance users are at increased risk for HIV and HCV infection. Still, many substance use treatment programs (SUTP) fail to offer HIV/HCV testing. The present secondary analysis of screening data from a multisite randomized trial of rapid HIV testing examines selfreported HIV/HCV testing patterns and serostatus of 2473 SUTP patients in 12 community-based sites that had not previously offered on-site testing. Results indicate that most respondents screened for the randomized trial tested more than a year prior to intake for HIV (52 %) and HCV (38 %). Prevalence rates were 3.6 and 30 % for HIV and HCV, respectively. The majority of participants that were HIV (52.2 %) and HCV-positive (40.5 %) reported having been diagnosed within the last 1-5 years. Multivariable logistic regression showed that members of high-risk groups were more likely to have tested. Bundled HIV/HCV testing and linkage to care issues are recommended for expanding testing in community-based SUTP settings.
Introduction
Injection and non-injection drug users remain at elevated risk for both human immunodeficiency (HIV) and hepatitis C (HCV) viral infections even as advances in testing and treatment have developed over time [1] [2] [3] [4] [5] [6] [7] [8] [9] . The Centers for Disease Control and Prevention (CDC) estimates that over one million people in the U.S. are living with HIV, and of those infected, greater than 200,000 (18 %) do not know of their seropositive status [10] [11] [12] [13] . Injection drug users account for nearly 15 % of new HIV infections [14] . Similarly, of the approximately 3.9 million individuals living with HCV in the US [15] , the majority (60 %) are unaware of their status [16, 17] . Injection drug use is the most prevalent risk behavior attributed to HCV infection, with an estimated 60 % of HCV positive individuals reporting a history of injection drug use in the US [15] . The identification of hard to reach HIV and/or HCV-positive substance users presents a significant challenge for disease prevention and treatment [18, 19] . This has critical implications for reducing disease transmission and improving the survival, health, and quality of life of infected persons through linkage to care [20] [21] [22] [23] [24] [25] .
Several recent policy initiatives recommend coupling HIV and/or HCV screening with other health services as a way of increasing testing, particularly among at-risk populations such as substance users [26] [27] [28] [29] . Furthermore, the CDC, along with state and local governments, has strongly encouraged or mandated (in the case of New York State) the offer of routine HIV testing in healthcare settings particularly in circumstances of increased risk, as is the case among substance users [30, 31] . Technological innovations such as rapid tests as well as increased awareness of the benefits of testing and treatment have enabled providers in a wider variety of settings to identify and seek care for infected individuals. Community-based substance use treatment programs constitute an important setting to offer testing and referral services for a segment of the population at increased risk for HIV and HCV.
Ironically, HIV testing in opioid treatment facilities has declined from 93 % in 2005 to 64 % in 2011, particularly in states that require pretest counseling and lack an opt-out approach to the informed consent procedures [32] . HCV testing during the same time period increased but largely due to off-site referrals [33] . Earlier findings estimated that fewer than half of U.S. substance use treatment programs offer on-site HIV testing services and about 29 % provide HCV testing to their patients [32] [33] [34] [35] [36] [37] [38] . Limited HIV and HCV testing options in community based settings represents a missed opportunity to reach high-risk and otherwise hard-to-reach populations such as substance users [4, 36, [39] [40] [41] . Nevertheless, prior studies have overwhelmingly relied on program administrators to provide data on the availability of on-site HIV testing rather than asking patients directly about their HIV and HCV screening behavior [32, 34, [42] [43] [44] . This introduces a potential reporting bias as these sources do not reflect testing penetration among the patient population.
Several authors have provided explanations for why HIV and HCV testing is not more widespread. They cite lack of time, lack of training, lack of funding for testing, and lack of capacity to treat or knowledge of where to refer for treatment [32, 43] . Others suggest that off-site referrals and a decline in funding for opioid treatment are key determinants that limit opportunities for identifying cases and linking patients to care [33] . Still, the notion of expanding HIV and HCV testing within substance use treatment settings has been contested and even considered by some to be a suboptimal use of resources because testing is offered in other venues seemingly accessible to substance users [45] . These debates and gaps in the literature raise an important question: what are the testing patterns and infection prevalence rates of substance use treatment patients in programs that do not offer onsite HIV and/or HCV testing?
This paper addresses this gap in knowledge by reporting findings regarding HIV and HCV testing history and seroprevalence rates among patients at community-based substance use treatment programs. The present study is a secondary analysis of participants' screening data gathered for the HIV Rapid Testing and Counseling in Drug Abuse Treatment study (CTN 0032) sponsored by the National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) [46] . The CTN 0032 clinical trial examined the effectiveness and cost-effectiveness of on-site rapid testing with and without risk reduction counseling as a strategy to increase HIV testing acceptance and receipt of results, as well as to reduce sexual risk behavior among substance use treatment patients. In that study, participants who were referred off-site to testing were significantly less likely to obtain their test results compared to participants who received on-site rapid testing and there was no significant difference is HIV sexual risk behavior between those who did and did not receive HIV risk behavior counseling [46] . A prior secondary analysis found that onsite HIV testing was effective across treatment modalities for achieving high rates of HIV testing and results feedback compared to offsite referral [47] . Most recently an evaluation of rapid HCV and HCV/HIV antibody testing in substance use treatment programs was shown to be cost-effective [48] . The aim of the present article is to identify what factors (demographic, substance use, treatment modality) impacted patient HIV and HCV test history and seropositivity.
Methods
The parent study, described in detail elsewhere [46] was a randomized clinical trial (RCT) conducted in 12 US community-based substance use treatment programs (CTPs) that, within 6 months prior to participating in the study, did not offer on-site HIV testing. Participant eligibility criteria AIDS Behav (2016) 20:204-214 205 for the RCT included being at least 18 years old, being HIV-negative or unaware of one's HIV status, and not having received result of an HIV test conducted in the past 12 months. Participant eligibility for the screening assessment was solely to be physically present at the CTP, therefore not all participants in the screening sample meet the RCT eligibility criteria. Screening was conducted over a 5 month period (January-May, 2009) where all substance use treatment patients and individuals presenting at intake assessments at the CTPs were screened, with consent, by research staff for study eligibility. Participants were recruited by research assistants at study sites by approaching patients in waiting rooms and treatment groups, and by self-referral. The brief screen assessed for HIV and HCV testing patterns in the past 5 years, knowledge of HIV and HCV status, demographics (gender, racial/ethnic background, age) and lifetime/past 12 months injection drug use. All individuals screened for the study were provided $5 for completing the screening questionnaire. Analyses for the present study were conducted using all screening data, regardless of whether individuals qualified for study participation (i.e. HIV testing in the past year).
Recruitment Sites
Recruitment occurred in 12 CTPs located in Tucson, AZ; Plainville and Danbury, CT; Baltimore, MD; Cape Girardeau, MO; Salisbury, NC; Santa Fe, NM; Portland, OR; Pittsburgh, PA; Columbia and West Columbia, SC; and Chesterfield, VA. Participating programs offered different modalities of treatment, including outpatient and intensive outpatient psychosocial (n = 6), opioid treatment (n = 3), and residential programs (n = 3). One of the residential sites also recruited a small number of participants from their on-site outpatient program. The parent study was approved by all study sites' local IRBs or the Western IRB.
CTP Demographics
All sites tracked the demographics including gender, race/ ethnicity and age group of their patient populations within the units from which recruitment was completed using clinic records. These data were used to compare the study sample to the CTP population.
Statistical Analysis
Chi square analyses were performed to examine whether the self-reported history of the timing of prior HIV and HCV testing and of their HIV and HCV status differed across gender, race/ethnicity, age, IDU status and modality of treatment program. Multiple logistic regression analyses were conducted to test the independent impacts of these factors (i.e. controlling for all other impacts) and explore interactions related to gender, race/ethnicity and age. The dependent measures for the logistic regressions were Ever HIV tested and Ever HCV tested. For multiple category predictors, contrasts based on the model were estimated to provide odds ratio estimates comparing all categories.
Results
Of the 2473 patients screened for the parent study, over half were males (58.8 %), most were White (55.6 %), followed by Black (27.1 %), and 10.4 % were Hispanic/ Latino. As shown in Table 1 , these proportions are comparable to the demographics of the treatment population of the 12 sites from which we recruited, with our screening sample having greater proportion of both Black and Hispanic participants than represented in the demographics of the treatment population. A sizable portion of the sample also had a history of injection drug use (43.3 %) and nearly a fifth had injected drugs in the previous 12 months (19.4 %). Most were screened at outpatient treatment centers (49.9 %), with the remainder of the sample screened at either opioid treatment programs (27.6 %), or at residential treatment facilities (22.5 %).
Self-Reported HIV Testing History and Serostatus
Twenty-one (0.8 %) of the 2473 individuals screened were excluded in the analysis of HIV testing history for the following reasons: 6 (0.2 %) did not provide answers to the HIV testing question and 15 (0.6 %) responded ''Don't Know'' to the question of having ever been tested. This resulted in a sample of 2452 for the assessment of HIV testing history. HIV status was only examined within the subgroup of participants that knew their HIV status. Six hundred twenty-one (25.1 %) of the individuals screened were excluded from the HIV-positive rate calculation for the following reasons: 497 (20.1 %) reported never having been tested, 43 (1.7 %) participants did not answer, and 60 (2.4 %) responded ''Don't Know'' to their HIV status, possibly because they did not pick up their results (though this was not directly queried). The resulting sample size for HIV status was 1852.
Self-Reported HIV Testing History
Most participants had their last HIV test more than a year prior to their interview (52.1 %, 1278/2452) and 27.6 % (677/2452) were tested in the past year. There were a Data represents information provided by the sites for participants accessing services from the date on which sites began actively recruiting to date of last randomization 41 , p \ 0.001) were all more likely to have been tested. There were significant differences in HIV testing by treatment modality (v 2 (4) = 153.14, p \ 0.001); participants from the opioid treatment programs were more likely, and those from residential treatment were less likely, to have been HIV tested prior to study screening.
The logistic regression examining HIV testing history indicated that the simple relationships by participant characteristics were maintained when adjusted for other demographic characteristics. In addition there was a statistically significant interaction of gender and race/ethnicity (v 2 (3) = 12.81, p = 0.005, see second and third columns of Table 3 for odds ratios and confidence intervals), but neither between gender and age (v 2 (1) = 6.76, p = 0.009).
Self-Reported HIV Serostatus
The overall self-report of HIV-positive status in the sample was 3.6 %. Most HIV-positive participants (52.2 %) were last tested within a year of study screening; 47.8 % were tested more than a year ago. The second and third columns of Table 4 show the HIV status by demographic characteristics. There were no differences in HIV status by gender v 
Self-Reported HCV Testing History and Serostatus
Seven participants (0.3 %) did not provide answers to the HCV testing history question and an additional 469 responded (19.0 %) ''Don't Know,'' resulting in a sample of 1997 for analyses of HCV testing history. There were 739 (29.9 %) who reported having never been tested for HCV, 86 (3.5 %) who reported having been tested but did not provide any information on their HCV status, and 163 (6.6 %) participants who responded that they did not know their HCV status, resulting in a sample of 1,485 for analysis of HCV status.
Self-Reported HCV Testing
As with HIV testing history, there were significant differences in the distribution of HCV testing by demographic characteristics (see Table 5 ). Similar to the pattern for HIV testing, women were more likely to have been HCV tested and more likely to have been tested recently Results of the logistic regression analysis of ever HCV testing showed that individuals with a history of injection drug use were over three times as likely as those who had no IDU history to have been HCV tested (OR 3.44 
Self-Reported HCV Status
The overall self-reported HCV-positive status in this study was 30.6 %. Of those HCV-positive, 40.5 % were diagnosed in the past year; 32.1 % between 1 and 5 years prior to study screening, and 27.4 % were diagnosed more than 5 years ago. The proportions by participant demographics are presented in columns 4 and 5 of with an injection drug history were HCV-positive whereas, the HCV-positive rate for those without any history of injection drug use was 4.3 % (v 2 (2) = 407.17, p \ 0.001).
Discussion
The present analysis confirms missed opportunities for HIV and HCV screening and diagnosis in settings serving substance users who are at high risk of acquiring these viral infections. First, findings suggest that substance use patients are not testing regularly despite being at heightened risk for HIV and HCV infection. To date, the focus of research on this topic has been on the availability of testing in treatment programs [32] [33] [34] [42] [43] [44] . This is the only study, to our knowledge, to show HIV and HCV testing patterns from the client perspective. Second, results indicate that members of groups at highest risk for HIV and HCV acquisition were more likely to have been tested, tested recently and frequently, and be aware of their serostatus, suggesting that risk-factor based screening may be occurring among high-risk populations. Nevertheless, a significant proportion of substance use patients had not been recently tested demonstrating the need for broader, more expanded routine screening approaches in community-based venues. This particular finding supports the expansion of both HIV and HCV testing in communitybased substance use treatment programs, which counters earlier suggestions that providing such testing would be duplicative of testing efforts in outside settings [45] . Moreover, the CDC's recommendations to expand routine testing of both HIV and HCV in health care settings and other community-based venues (i.e. STD clinics, emergency rooms and primary care clinics) are especially relevant for increasing testing among substance users who remain at elevated risk of infection [26, 49] but may not be prepared to seek substance use treatment services. The present study's findings suggest that additional strategies are needed to increase uptake of HIV and HCV testing among persons with substance use disorders, particularly at outpatient and residential substance use treatment programs. Screening high-risk populations such as patients in substance use treatment programs will increase the proportion of Americans who are aware of their HIV or HCV diagnosis. However, testing is just the first step in the continuum of care. Resources are vitally needed to ensure It is also clear from our findings that HIV testing and knowledge of HIV status remain more common than HCV testing and knowledge of HCV status, despite the threefold to fivefold higher prevalence of HCV in the US. This finding reflects disparities in HCV among particular at-risk groups and is consistent with general trends reported elsewhere [50] . The advent of improved HCV testing alternatives including a rapid testing kit with an oral swab (similar to that increasingly standard in HIV testing) along with new treatment options are poised to significantly improve screening and treatment options [48, [51] [52] [53] . As HCV testing and drug therapies become more widely available, the uptake of HCV testing and treatment is likely to increase significantly [54, 55] . Furthermore, expanded HIV and HCV prevention, care and treatment options increase opportunities for identifying and treating co-morbid conditions when bundled.
Limitations
This study has several limitations including the limited number of variables in the brief study screening tool, which were primarily intended to capture a minimal amount of information to determine eligibility in the larger RCT. Moreover, while we found that many of the respondents who were positive reported a recent diagnosis, we do not know how late in the disease progression they were identified because we did not collect biomarker information such as CD4 and viral load. An additional limitation is selfreports of HIV and HCV serostatus, which may not exhibit high concordance with testing results, although some research has found high rates of concordance in HIV and HCV self-reported serostatus and testing results [56] . We also did not collect comprehensive data in the screening instrument regarding substance use patterns. Therefore, we were unable to distinguish between substance use types and severity. Finally, whereas this is a multi-site trial with a relatively large sample size, it is not a random sample of either substance use treatment centers or patients.
Conclusion
To conclude, our findings lend credence to addressing a key opportunity for improving services to persons at risk for HIV and HCV by augmenting the capacity in substance use treatment programs for testing and linkage to care. The present analysis demonstrates the potential for communitybased substance use treatment programs to identify substance users at-risk for HIV and HCV infection. Once identified as positive, however substance users often encounter significant impediments in accessing care and treatment services due to issues such as housing insecurity, mental illness, stigma and discrimination in health care settings, transportation challenges, poverty and histories of incarceration [22, 23] . Therefore, while community-based substance use treatment programs may be appropriate venues for identifying new cases, a considerable gap remains in linking and retaining patients in care. Moreover, access to high quality care and services that are attentive to the unique needs of substance users is vital to (a) realizing optimal results in both HIV and HCV, (b) reducing the incidence of late diagnoses, (c) extending life expectancy, (d) improving health outcomes and quality of life and (e) decreasing the use of costly medical services [4, 33, 57, 58] . In understanding the prevalence of HIV and HCV of substance users, more integrated approaches can be developed to advance linkage to care and retention for HIV and/or HCV-positive individuals and their sexual or substance-using partners [18, 27-29, 54, 59] . The results herein suggest future efforts to both identify new cases through testing and to actively link those newly diagnosed or of previously known HIV and/or HCV-positive status to appropriate care and treatment may benefit from models that offer comprehensive/wrap-around services within community-based substance use treatment programs [60] [61] [62] . This may require establishing a multi-service model in which substance use treatment services are co-located with onsite health services or combined with case management. Implementation of the Affordable Care Act may facilitate these efforts.
